HUE044605T2 - RP/SP gemcitabin-[fenil-(benziloxi-L-alaninil)]-foszfát keveréke - Google Patents

RP/SP gemcitabin-[fenil-(benziloxi-L-alaninil)]-foszfát keveréke

Info

Publication number: HUE044605T2
Authority: HU; Hungary
Prior art keywords: alaninyl; gemcitabine; benzyloxy; phenyl; phosphate
Prior art date: 2012-11-16

Application number

Other languages

English (en)

Inventor

Christopher Mcguigan

Fabrizio Pertusati

Original Assignee

Univ College Cardiff Consultants Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-11-16

Filing date

2013-11-15

Publication date

2019-11-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49622844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE044605(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-11-16 Priority claimed from GBGB1220666.0A external-priority patent/GB201220666D0/en

2013-04-23 Priority claimed from GB201307314A external-priority patent/GB201307314D0/en

2013-11-15 Application filed by Univ College Cardiff Consultants Ltd filed Critical Univ College Cardiff Consultants Ltd

2019-11-28 Publication of HUE044605T2 publication Critical patent/HUE044605T2/hu

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J27/00—Catalysts comprising the elements or compounds of halogens, sulfur, selenium, tellurium, phosphorus or nitrogen; Catalysts comprising carbon compounds
- B01J27/06—Halogens; Compounds thereof
- B01J27/128—Halogens; Compounds thereof with iron group metals or platinum group metals
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y20/00—Nanooptics, e.g. quantum optics or photonic crystals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01S—DEVICES USING THE PROCESS OF LIGHT AMPLIFICATION BY STIMULATED EMISSION OF RADIATION [LASER] TO AMPLIFY OR GENERATE LIGHT; DEVICES USING STIMULATED EMISSION OF ELECTROMAGNETIC RADIATION IN WAVE RANGES OTHER THAN OPTICAL
- H01S5/00—Semiconductor lasers
- H01S5/30—Structure or shape of the active region; Materials used for the active region
- H01S5/34—Structure or shape of the active region; Materials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well [SQW] lasers, multiple quantum well [MQW] lasers or graded index separate confinement heterostructure [GRINSCH] lasers
- H01S5/343—Structure or shape of the active region; Materials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well [SQW] lasers, multiple quantum well [MQW] lasers or graded index separate confinement heterostructure [GRINSCH] lasers in AIIIBV compounds, e.g. AlGaAs-laser, InP-based laser
- H01S5/34326—Structure or shape of the active region; Materials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well [SQW] lasers, multiple quantum well [MQW] lasers or graded index separate confinement heterostructure [GRINSCH] lasers in AIIIBV compounds, e.g. AlGaAs-laser, InP-based laser with a well layer based on InGa(Al)P, e.g. red laser

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Chemical Kinetics & Catalysis (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Virology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Nanotechnology (AREA)
Bioinformatics & Cheminformatics (AREA)
Physics & Mathematics (AREA)
Optics & Photonics (AREA)
Crystallography & Structural Chemistry (AREA)
Biophysics (AREA)
Materials Engineering (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Reproductive Health (AREA)
AIDS & HIV (AREA)
Endocrinology (AREA)
Tropical Medicine & Parasitology (AREA)
Saccharide Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Catalysts (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Epidemiology (AREA)
Peptides Or Proteins (AREA)

HUE17169878 2012-11-16 2013-11-15 RP/SP gemcitabin-[fenil-(benziloxi-L-alaninil)]-foszfát keveréke HUE044605T2 (hu)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB1220666.0A GB201220666D0 (en)	2012-11-16	2012-11-16	Process for preparing chemical compounds
GB201307314A GB201307314D0 (en)	2013-04-23	2013-04-23	Process for preparing chemical compounds

Publications (1)

Publication Number	Publication Date
HUE044605T2 true HUE044605T2 (hu)	2019-11-28

Family

ID=49622844

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
HUE16195036A HUE033335T2 (hu)	2012-11-16	2013-11-15	RP/SP gemcitabin-[fenil-(benzil-oxi-L-alaninil)]-foszfát keverék
HUE17169878 HUE044605T2 (hu)	2012-11-16	2013-11-15	RP/SP gemcitabin-[fenil-(benziloxi-L-alaninil)]-foszfát keveréke

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
HUE16195036A HUE033335T2 (hu)	2012-11-16	2013-11-15	RP/SP gemcitabin-[fenil-(benzil-oxi-L-alaninil)]-foszfát keverék

Country Status (28)

Country	Link
US (3)	US10005810B2 (hu)
EP (3)	EP3235824B1 (hu)
JP (5)	JP2016506371A (hu)
KR (1)	KR20150103669A (hu)
CN (2)	CN111592577A (hu)
AU (1)	AU2013346515B2 (hu)
CA (1)	CA2891266C (hu)
CL (1)	CL2015001307A1 (hu)
CY (2)	CY1119161T1 (hu)
DK (2)	DK3150616T3 (hu)
EA (1)	EA028871B1 (hu)
ES (3)	ES2618732T3 (hu)
HR (2)	HRP20170791T1 (hu)
HU (2)	HUE033335T2 (hu)
IL (1)	IL238792A (hu)
IN (1)	IN2015DN04090A (hu)
LT (2)	LT3235824T (hu)
MX (1)	MX374779B (hu)
MY (1)	MY176133A (hu)
NZ (1)	NZ708177A (hu)
PH (1)	PH12015501090B1 (hu)
PL (2)	PL3150616T3 (hu)
PT (2)	PT3235824T (hu)
RS (2)	RS56038B1 (hu)
SG (3)	SG10201510324YA (hu)
SI (2)	SI3150616T1 (hu)
SM (2)	SMT201700349T1 (hu)
WO (1)	WO2014076490A1 (hu)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0317009D0 (en)	2003-07-21	2003-08-27	Univ Cardiff	Chemical compounds
SI3150616T1 (sl) *	2012-11-16	2017-08-31	University College Cardiff Consultants Limited	Mešanica rp/sp gemcitabin-(fenil-(benziloksi-l-alaninil))-fosfata
US10034893B2 (en)	2013-02-01	2018-07-31	Enanta Pharmaceuticals, Inc.	5, 6-D2 uridine nucleoside/tide derivatives
CN105934438A (zh) *	2013-11-27	2016-09-07	艾登尼克斯药业有限公司	用于治疗肝癌的核苷酸
CN105153257B (zh) *	2014-06-12	2019-03-05	正大天晴药业集团股份有限公司	索非布韦的制备方法
EP3160978B1 (en) *	2014-06-25	2020-07-29	NuCana plc	Gemcitabine prodrugs
WO2015198059A1 (en)	2014-06-25	2015-12-30	Nucana Biomed Limited	Formulation comprising a gemcitabine-prodrug
CN105254694B (zh) *	2014-07-14	2018-11-27	正大天晴药业集团股份有限公司	氘代核苷衍生物
ES2830784T3 (es)	2014-07-22	2021-06-04	NuCana plc	Proceso para la preparación de gemcitabina-[fenil(benzoxi-L-alanil)]fosfato
CN106661074A (zh) *	2014-07-31	2017-05-10	桑多斯股份公司	磷酰胺的合成
US9675632B2 (en)	2014-08-26	2017-06-13	Enanta Pharmaceuticals, Inc.	Nucleoside and nucleotide derivatives
CN105461774B (zh) *	2014-09-30	2020-11-24	江苏豪森药业集团有限公司	索非布韦的制备方法
CN105461773B (zh) *	2014-09-30	2020-12-01	江苏豪森药业集团有限公司	索非布韦的制备方法及其中间体
GB201417644D0 (en) *	2014-10-06	2014-11-19	Nucana Biomed Ltd	Method of separating phosphate diastereoisomers
WO2016073756A1 (en)	2014-11-06	2016-05-12	Enanta Pharmaceuticals, Inc.	Deuterated nucleoside/tide derivatives
US9732110B2 (en)	2014-12-05	2017-08-15	Enanta Pharmaceuticals, Inc.	Nucleoside and nucleotide derivatives
CA3182565A1 (en)	2015-03-06	2016-09-15	Atea Pharmaceuticals, Inc.	.beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
WO2016151542A1 (en)	2015-03-26	2016-09-29	Quimica Sintetica, S.A.	Nucleoside phosphoramidates useful for the treatment of viral infections and preparation thereof
CN106397515B (zh) *	2015-07-28	2021-05-11	广东东阳光药业有限公司	一种改良的索菲布韦制备方法
CN106543252A (zh) *	2015-09-16	2017-03-29	博瑞生物医药（苏州）股份有限公司	核苷氨基磷酸酯类前药的制备方法及其中间体
CN106543220A (zh)	2015-09-16	2017-03-29	博瑞生物医药（苏州）股份有限公司	氨基磷酸酯化合物及其制备方法和晶体
CN112156102B (zh) *	2015-09-16	2023-10-03	济南高合医疗科技有限公司	一种nuc-1031单一异构体的晶型及其制备方法
PH12018500691B1 (en) *	2015-10-05	2022-08-10	NuCana plc	Combination therapy
WO2017090264A1 (ja) *	2015-11-27	2017-06-01	大原薬品工業株式会社	５－アザシチジン又は其の２'－デオキシ体の５'位ジベンジル燐酸エステル
RS62593B1 (sr) *	2015-12-11	2021-12-31	NuCana plc	Dijastereoselektivna sinteza derivata fosfata i proleka gemcitabina nuc-1031
GB201522771D0 (en) *	2015-12-23	2016-02-03	Nucana Biomed Ltd	Crystalline form of a phosphate derivative
GB201609602D0 (en) *	2016-06-01	2016-07-13	Nucuna Biomed Ltd	Chemical compounds
US10202412B2 (en)	2016-07-08	2019-02-12	Atea Pharmaceuticals, Inc.	β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
WO2018013937A1 (en)	2016-07-14	2018-01-18	Atea Pharmaceuticals, Inc.	Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
US10239910B2 (en) *	2016-07-20	2019-03-26	Optimus Drugs (P) Limited	Process for the preparation of sofosbuvir
CN107652342A (zh) *	2016-07-23	2018-02-02	江苏万高药业股份有限公司	核苷氨基磷酸酯类前药的多晶型及其制备方法
WO2018048937A1 (en)	2016-09-07	2018-03-15	Atea Pharmaceuticals, Inc.	2'-substituted-n6-substituted purine nucleotides for rna virus treatment
US10266558B2 (en) *	2016-10-07	2019-04-23	Alexandre Vasilievich Ivachtchenko	Macroheterocyclic nucleoside derivatives and their analogues, production and use thereof
CN109863160B (zh) *	2016-12-23	2022-06-07	四川科伦博泰生物医药股份有限公司	核苷磷酸类化合物及其制备方法和用途
IL288737B (en)	2017-02-01	2022-09-01	Atea Pharmaceuticals Inc	Hemisulfate nucleotide salt for treatment of hepatitis c virus
GB201709471D0 (en)	2017-06-14	2017-07-26	Nucana Biomed Ltd	Diastereoselective synthesis of hosphate derivatives
EP3773753A4 (en)	2018-04-10	2021-12-22	ATEA Pharmaceuticals, Inc.	TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS
EP3808752A4 (en)	2018-06-12	2022-03-09	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	PHOSPHONYMIDE ESTER COMPOUND, SALT THEREOF, RELATIVE CRYSTAL FORM THEREOF, PROCESS FOR THEIR PREPARATION AND THEIR USE
US10874687B1 (en)	2020-02-27	2020-12-29	Atea Pharmaceuticals, Inc.	Highly active compounds against COVID-19
RU2740058C1 (ru) *	2020-06-26	2020-12-31	Общество С Ограниченной Ответственностью "Технология Лекарств"	Способ получения софосбувира и фосфорамидаты
CN112409431B (zh) *	2020-12-07	2023-04-21	武汉伯瑞恒医药科技有限公司	阿糖胞苷结构类似物及其制备方法和用途
IL308921A (en)	2021-06-17	2024-01-01	Atea Pharmaceuticals Inc	Combination anti-HCV therapy is beneficial
CN113549076B (zh) *	2021-07-23	2022-12-06	中国药科大学	一种多取代嘌呤类化合物及其制备方法和应用
WO2024107859A1 (en) *	2022-11-15	2024-05-23	Rome Therapeutics, Inc.	Cyclopentene-oxymethylene phosphonamidates and related compounds and their use in treating medical conditions

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6703396B1 (en)	1990-02-01	2004-03-09	Emory University	Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5728575A (en)	1990-02-01	1998-03-17	Emory University	Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US5204466A (en) *	1990-02-01	1993-04-20	Emory University	Method and compositions for the synthesis of bch-189 and related compounds
IL137164A0 (en)	1998-01-23	2001-07-24	Newbiotics Inc	Enzyme catalyzed therapeutic agents
US7462605B2 (en)	1998-01-23	2008-12-09	Celmed Oncology (Usa), Inc.	Phosphoramidate compounds and methods of use
JP2005522443A (ja)	2002-02-14	2005-07-28	フアーマセツト・リミテツド	改変フッ素化ヌクレオシド類似体
WO2004041203A2 (en)	2002-11-04	2004-05-21	Xenoport, Inc.	Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
GB0317009D0 (en) *	2003-07-21	2003-08-27	Univ Cardiff	Chemical compounds
GB0505781D0 (en) *	2005-03-21	2005-04-27	Univ Cardiff	Chemical compounds
WO2007020193A2 (en) *	2005-08-15	2007-02-22	F. Hoffmann-La Roche Ag	Antiviral phosphoramidates of 4 ' -substituted pronucleotides
GB0623493D0 (en) *	2006-11-24	2007-01-03	Univ Cardiff	Chemical compounds
US7964580B2 (en) *	2007-03-30	2011-06-21	Pharmasset, Inc.	Nucleoside phosphoramidate prodrugs
PA8852101A1 (es) *	2008-12-08	2010-07-27	Medivir Ab	Nucleótidos uracil ciclopropílicos
US8759318B2 (en) *	2009-01-09	2014-06-24	Inhibitex, Inc.	Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections
TWI583692B (zh) *	2009-05-20	2017-05-21	基利法瑪席特有限責任公司	核苷磷醯胺
UY33310A (es)	2010-03-31	2011-10-31	Pharmasset Inc	Sintesis estereoselectiva de activos que contienen fosforo
AU2011282241B2 (en)	2010-07-19	2015-07-30	Gilead Sciences, Inc.	Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
NZ607996A (en) *	2010-09-22	2014-07-25	Alios Biopharma Inc	Substituted nucleotide analogs
CA2819041A1 (en) *	2010-12-22	2012-06-28	Alios Biopharma, Inc.	Cyclic nucleotide analogs
DK3031812T3 (en) *	2011-03-01	2018-09-17	NuCana plc	CHEMICAL COMPOUNDS
EP2680859B1 (en) *	2011-03-02	2022-04-27	Jerome Schentag	Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis c virus infection
EP2765997A4 (en) *	2011-10-14	2015-06-24	Stc Unm	POROUS NANOPARTICLE-SUPPORTED LIPID DOUBLE LAYERS (PROTOCOLS) FOR THE TARGETED RELEASE BY TRANSDERMAL RELEASE AND USE METHOD THEREFOR
SI3150616T1 (sl)	2012-11-16	2017-08-31	University College Cardiff Consultants Limited	Mešanica rp/sp gemcitabin-(fenil-(benziloksi-l-alaninil))-fosfata
AU2014302711A1 (en) *	2013-06-26	2015-12-10	Alios Biopharma, Inc.	Substituted nucleosides, nucleotides and analogs thereof
LT3043803T (lt)	2013-09-11	2022-08-10	Emory University	Nukleotidų ir nukleozidų kompozicijos ir jų panaudojimas
WO2015054465A1 (en) *	2013-10-11	2015-04-16	Alios Biopharma, Inc.	Substituted nucleosides, nucleotides and analogs thereof
CN105934438A (zh)	2013-11-27	2016-09-07	艾登尼克斯药业有限公司	用于治疗肝癌的核苷酸
JP2016538306A (ja) *	2013-11-27	2016-12-08	アメリカ合衆国	複素環化合物及びその使用方法
WO2015198059A1 (en)	2014-06-25	2015-12-30	Nucana Biomed Limited	Formulation comprising a gemcitabine-prodrug
EP3160978B1 (en)	2014-06-25	2020-07-29	NuCana plc	Gemcitabine prodrugs
ES2830784T3 (es)	2014-07-22	2021-06-04	NuCana plc	Proceso para la preparación de gemcitabina-[fenil(benzoxi-L-alanil)]fosfato
GB201417644D0 (en)	2014-10-06	2014-11-19	Nucana Biomed Ltd	Method of separating phosphate diastereoisomers
SMT201800303T1 (it)	2015-05-14	2018-07-17	NuCana plc	Trattamenti per il cancro
PH12018500691B1 (en)	2015-10-05	2022-08-10	NuCana plc	Combination therapy
RS62593B1 (sr)	2015-12-11	2021-12-31	NuCana plc	Dijastereoselektivna sinteza derivata fosfata i proleka gemcitabina nuc-1031
HUE050290T2 (hu)	2015-12-23	2020-11-30	NuCana plc	Kombinált terápia
GB201522771D0 (en)	2015-12-23	2016-02-03	Nucana Biomed Ltd	Crystalline form of a phosphate derivative
CA3008769A1 (en)	2015-12-23	2017-06-29	NuCana plc	Combination therapy comprising nuc-1031 and cisplatin
GB201713914D0 (en)	2017-08-30	2017-10-11	Nucana Biomed Ltd	Combination therapy
JP2020171815A (ja) *	2020-07-29	2020-10-22	株式会社ユニバーサルエンターテインメント	プログラム

2013
- 2013-11-15 SI SI201330652T patent/SI3150616T1/sl unknown
- 2013-11-15 EA EA201590955A patent/EA028871B1/ru unknown
- 2013-11-15 US US14/442,987 patent/US10005810B2/en active Active
- 2013-11-15 MX MX2015006195A patent/MX374779B/es active IP Right Grant
- 2013-11-15 MY MYPI2015001314A patent/MY176133A/en unknown
- 2013-11-15 ES ES13792965.9T patent/ES2618732T3/es active Active
- 2013-11-15 HU HUE16195036A patent/HUE033335T2/hu unknown
- 2013-11-15 HU HUE17169878 patent/HUE044605T2/hu unknown
- 2013-11-15 RS RS20170506A patent/RS56038B1/sr unknown
- 2013-11-15 DK DK16195036.5T patent/DK3150616T3/en active
- 2013-11-15 ES ES16195036.5T patent/ES2627195T3/es active Active
- 2013-11-15 SM SM20170349T patent/SMT201700349T1/it unknown
- 2013-11-15 AU AU2013346515A patent/AU2013346515B2/en not_active Ceased
- 2013-11-15 WO PCT/GB2013/053018 patent/WO2014076490A1/en not_active Ceased
- 2013-11-15 CA CA2891266A patent/CA2891266C/en active Active
- 2013-11-15 EP EP17169878.0A patent/EP3235824B1/en active Active
- 2013-11-15 KR KR1020157015861A patent/KR20150103669A/ko not_active Ceased
- 2013-11-15 RS RS20190549A patent/RS58849B1/sr unknown
- 2013-11-15 IN IN4090DEN2015 patent/IN2015DN04090A/en unknown
- 2013-11-15 CN CN202010526209.7A patent/CN111592577A/zh active Pending
- 2013-11-15 SG SG10201510324YA patent/SG10201510324YA/en unknown
- 2013-11-15 PT PT17169878T patent/PT3235824T/pt unknown
- 2013-11-15 LT LTEP17169878.0T patent/LT3235824T/lt unknown
- 2013-11-15 SM SM20190341T patent/SMT201900341T1/it unknown
- 2013-11-15 NZ NZ708177A patent/NZ708177A/en not_active IP Right Cessation
- 2013-11-15 LT LTEP16195036.5T patent/LT3150616T/lt unknown
- 2013-11-15 SI SI201331437T patent/SI3235824T1/sl unknown
- 2013-11-15 PL PL16195036T patent/PL3150616T3/pl unknown
- 2013-11-15 DK DK17169878.0T patent/DK3235824T3/da active
- 2013-11-15 PL PL17169878T patent/PL3235824T3/pl unknown
- 2013-11-15 SG SG11201503750YA patent/SG11201503750YA/en unknown
- 2013-11-15 ES ES17169878T patent/ES2725491T3/es active Active
- 2013-11-15 JP JP2015542357A patent/JP2016506371A/ja active Pending
- 2013-11-15 PT PT161950365T patent/PT3150616T/pt unknown
- 2013-11-15 EP EP16195036.5A patent/EP3150616B1/en active Active
- 2013-11-15 EP EP13792965.9A patent/EP2920192B1/en not_active Not-in-force
- 2013-11-15 CN CN201380069952.2A patent/CN104903339A/zh active Pending
- 2013-11-15 SG SG10201510322UA patent/SG10201510322UA/en unknown
2015
- 2015-05-13 IL IL238792A patent/IL238792A/en active IP Right Grant
- 2015-05-14 CL CL2015001307A patent/CL2015001307A1/es unknown
- 2015-05-15 PH PH12015501090A patent/PH12015501090B1/en unknown
2017
- 2017-05-24 CY CY20171100539T patent/CY1119161T1/el unknown
- 2017-05-29 HR HRP20170791TT patent/HRP20170791T1/hr unknown
- 2017-08-10 JP JP2017154931A patent/JP2018009000A/ja not_active Withdrawn
2018
- 2018-05-31 US US15/994,378 patent/US11040997B2/en active Active
2019
- 2019-05-06 HR HRP20190831TT patent/HRP20190831T1/hr unknown
- 2019-05-09 CY CY20191100503T patent/CY1121663T1/el unknown
- 2019-06-18 JP JP2019112739A patent/JP2019196360A/ja active Pending
2020
- 2020-10-12 JP JP2020171815A patent/JP7519259B2/ja active Active
2021
- 2021-05-18 US US17/323,367 patent/US20220033433A1/en not_active Abandoned
2023
- 2023-01-20 JP JP2023007007A patent/JP2023052536A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
JP7519259B2 (ja)	2024-07-19
PL3235824T3 (pl)	2019-09-30
CL2015001307A1 (es)	2015-12-11
CY1119161T1 (el)	2018-02-14
MX2015006195A (es)	2015-12-08
IN2015DN04090A (hu)	2015-10-09
HUE033335T2 (hu)	2017-11-28
PH12015501090B1 (en)	2019-01-30
BR112015011155A2 (pt)	2017-07-11
IL238792A0 (en)	2015-06-30
JP2021020919A (ja)	2021-02-18
PT3150616T (pt)	2017-06-09
HRP20170791T1 (hr)	2017-08-25
PT3235824T (pt)	2019-05-30
SMT201700349T1 (it)	2017-09-07
ES2725491T3 (es)	2019-09-24
SG10201510324YA (en)	2016-01-28
KR20150103669A (ko)	2015-09-11
WO2014076490A1 (en)	2014-05-22
LT3235824T (lt)	2019-07-10
CN111592577A (zh)	2020-08-28
CY1121663T1 (el)	2020-07-31
US10005810B2 (en)	2018-06-26
SMT201900341T1 (it)	2019-07-11
EA201590955A1 (ru)	2015-08-31
DK3150616T3 (en)	2017-06-06
JP2023052536A (ja)	2023-04-11
EP3150616A1 (en)	2017-04-05
RS56038B1 (sr)	2017-09-29
AU2013346515B2 (en)	2017-05-25
NZ708177A (en)	2017-08-25
JP2018009000A (ja)	2018-01-18
SI3235824T1 (sl)	2019-08-30
US20180273575A1 (en)	2018-09-27
MX374779B (es)	2025-03-06
DK3235824T3 (da)	2019-05-20
ES2627195T3 (es)	2017-07-27
US11040997B2 (en)	2021-06-22
CA2891266A1 (en)	2014-05-22
SI3150616T1 (sl)	2017-08-31
JP2019196360A (ja)	2019-11-14
EP3150616B1 (en)	2017-05-10
SG11201503750YA (en)	2015-06-29
EP3235824B1 (en)	2019-03-27
CN104903339A (zh)	2015-09-09
EA028871B1 (ru)	2018-01-31
IL238792A (en)	2017-09-28
US20220033433A1 (en)	2022-02-03
EP3235824A1 (en)	2017-10-25
HK1210784A1 (en)	2016-05-06
LT3150616T (lt)	2017-07-25
US20150291650A1 (en)	2015-10-15
EP2920192A1 (en)	2015-09-23
JP2016506371A (ja)	2016-03-03
CA2891266C (en)	2020-12-08
MY176133A (en)	2020-07-24
ES2618732T3 (es)	2017-06-22
HRP20190831T1 (hr)	2019-08-23
RS58849B1 (sr)	2019-07-31
SG10201510322UA (en)	2016-01-28
EP2920192B1 (en)	2017-02-22
AU2013346515A1 (en)	2015-06-04
PH12015501090A1 (en)	2015-07-27
PL3150616T3 (pl)	2017-09-29

Publication	Publication Date	Title
PT3235824T (pt)	2019-05-30	Mistura de rp/sp gencitabina-[fenil-(benziloxi-l-alaninil)]-fosfato
IL276761A (en)	2020-10-29	Methods of inducing coma
SG11201405573WA (en)	2014-11-27	Production of graphene
EP2834247A4 (en)	2016-03-30	PREPARATION OF TICAGRELOR
ZA201406082B (en)	2019-01-30	Use of ccr3-inhibitors
PL2900303T3 (pl)	2021-01-11	Inhalator
IL242314A (en)	2016-08-31	Iap inhibitors
GB201311220D0 (en)	2013-08-14	Improved structure of shoe
ZA201209245B (en)	2013-08-28	Rubber mixture
IL219244A0 (en)	2012-07-31	Splitting of user-lists
GB201501016D0 (en)	2015-03-04	Preparation of 18F-fluciclovine
PL2888228T3 (pl)	2019-10-31	Inhibitory oddziaływania CD40-TRAF6
GB2503216B (en)	2014-05-14	Continuity of content
EP2804612A4 (en)	2015-09-02	THERAPEUTIC USES OF TETRACHLORODECAOXYGEN (TCDO)
GB201312378D0 (en)	2013-08-21	Structure of shoe
PT2846806T (pt)	2018-01-29	Tratamento para depressão respiratória
GB201207907D0 (en)	2012-06-20	Treatment of depression
EP2879681A4 (en)	2015-12-23	INDOINDUBSTITUTED PYRROLOPYRIMIDINYL HIBITORS OF UBA6
GB201209895D0 (en)	2012-07-18	Use of a composition
ZA201104679B (en)	2012-03-28	Suppression of cancers
TWM433525U (en)	2012-07-11	Structure of calorifier
TWM438663U (en)	2012-10-01	Mouse capable of adjusting sound volume
AU2012905067A0 (en)	2012-12-06	IMPROVED INHIBITORS OF Grb7
GB201222952D0 (en)	2013-01-30	Treatent of cancer
GB201204590D0 (en)	2012-05-02	Prodrugs of thiazolamine compounds